Candel therapeutics receives fda regenerative medicine advanced therapy designation for can-2409 for the treatment of prostate cancer

Needham, mass., may 28, 2025 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the u.s. food and drug administration (fda) has granted regenerative medicine advanced therapy (rmat) designation to can-2409 (aglatimagene besadenovec), the company's biological immunotherapy lead candidate, for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease. can-2409 was also previously granted fda fast track designation for the same indication.
CADL Ratings Summary
CADL Quant Ranking